Cargando…

The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer

Tumor metabolism is a thrilling discipline that focuses on mechanisms used by cancer cells to earn crucial building blocks and energy to preserve growth and overcome resistance to various treatment modalities. At the same time, therapies directed specifically against aberrant signalling pathways dri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poliaková, Michaela, Aebersold, Daniel M., Zimmer, Yitzhak, Medová, Michaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817809/ https://www.ncbi.nlm.nih.gov/pubmed/29455660 http://dx.doi.org/10.1186/s12943-018-0798-9

Ejemplares similares

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response — Biological and Clinical Aspects
por: Medová, Michaela, et al.
Publicado: (2013)

CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
por: Hovhannisyan, Lusine, et al.
Publicado: (2023)

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models
por: Nisa, Lluís, et al.
Publicado: (2017)

Profiling Invasiveness in Head and Neck Cancer: Recent Contributions of Genomic and Transcriptomic Approaches
por: Nisa, Lluís, et al.
Publicado: (2015)

Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy—A Systematic Review
por: Schanne, Daniel H., et al.
Publicado: (2022)

A Comparative Analysis of Individual RAS Mutations in Cancer Biology
por: Muñoz-Maldonado, Carmen, et al.
Publicado: (2019)

Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology
por: Zimmer, Yitzhak, et al.
Publicado: (2020)

Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer
por: Piguet, Anne-Christine, et al.
Publicado: (2015)

Deciphering MET‐dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomics
por: Bensimon, Ariel, et al.
Publicado: (2020)

ProtRank: bypassing the imputation of missing values in differential expression analysis of proteomic data
por: Medo, Matúš, et al.
Publicado: (2019)

An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies
por: Orlando, Eleonora, et al.
Publicado: (2022)

Correction: An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies
por: Orlando, Eleonora, et al.
Publicado: (2023)

Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injury
por: Melin, Nicolas, et al.
Publicado: (2021)

A DNA-PK phosphorylation site on MET regulates its signaling interface with the DNA damage response
por: Koch, Jonas P., et al.
Publicado: (2023)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
por: Dervisis, Nikolaos, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
por: Alves, Raquel, et al.
Publicado: (2021)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
por: Kloth, J S L, et al.
Publicado: (2015)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Gupta, Sachin, et al.
Publicado: (2008)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cells
por: Nita, Izabela, et al.
Publicado: (2017)

Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
por: Jackson, Klarissa D., et al.
Publicado: (2018)

Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
por: Montor, Wagner Ricardo, et al.
Publicado: (2018)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
por: Hill, Andrew, et al.
Publicado: (2016)

Chaperone-mediated destruction of erbB2: relevance to tyrosine kinase inhibitors
por: Gee, Julia MW
Publicado: (2002)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective
por: Russo, Eleonora, et al.
Publicado: (2021)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Tan, Hor-Yue, et al.
Publicado: (2018)

Reversing multidrug resistance by tyrosine kinase inhibitors
por: He, Miao, et al.
Publicado: (2012)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Enhancing CRISPR deletion via pharmacological delay of DNA-PKcs
por: Bosch-Guiteras, Núria, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment
por: Ahmadieh, Hala, et al.
Publicado: (2013)

Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy
por: Amit, Ido, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_i1eoi92gmrneu0q7ni47ln6ehb